NCT02174978View on ClinicalTrials.gov

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

FMP012 with AS01B adjuvant system

Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)

OTHER

P falciparum Controlled Human Malaria Infection (CHMI)

Trial Locations (1)

20910

Clinical Trials Center, WRAIR, Silver Spring

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

United States Agency for International Development (USAID)

FED

collaborator

Military Infectious Diseases Research Program (MIDRP)

NETWORK

collaborator

GlaxoSmithKline

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED

NCT02174978 - Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults | Biotech Hunter | Biotech Hunter